advertisement

Topcon

11.4 Prostaglandins (31)

Showing records 1 to 25

Display all abstracts in classification 11.4 Prostaglandins

Search within classification 11.4 Prostaglandins
14982 The effect of unoprostone isopropyl on Ca2+ release-activated Ca2+ currents in cultured monkey trabecular meshwork cells and ciliary muscle cells
Shimura M; Yasuda K; Nakzawa T; Kashiwagi K
Journal of Ocular Pharmacology and Therapeutics 2006; 22: 219-226
15138 Prostaglandin F2α, but not latanoprost, increases the Ca2+ sensitivity of the pig iris sphincter muscle
Hasegawa Y; Nishimura J; Niiro N; Hirano K; Ishibashi T; Kanaide H
Investigative Ophthalmology and Visual Science 2006; 47: 4865-4871
14526 Red blood cell (RBC) surface acetylcholinesterase showing a hemorheological pattern during glaucoma treatment
Cicco G; Vetrugno M; Rotelli MT; Sborgia G; Pennetta M; Vico PP; Memeo V; Nitti L; Sborgia C
Clinical Hemorheology and Microcirculation 2006; 35: 149-154
14658 Effect of latanoprost for normal-tension glaucoma by measuring the intraocular pressure at fixed time of day
Mima A; Hata H; Murao F; Shiota H
Japanese Journal of Clinical Ophthalmology 2006; 60: 1613-1616
15284 Changes in glaucoma treatment and achieved IOP after introduction of new glaucoma medication
van der Valk R; Schouten JS; Webers CA; Hendrikse F; Prins MH
Graefe's Archive for Clinical and Experimental Ophthalmology 2006; 244: 1267-1272
15220 Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
Cantor LB; Hoop J; Morgan L; WuDunn D; Catoira Y; Bimatoprost-Travoprost Study Group
British Journal of Ophthalmology 2006; 90: 1370-1373
15255 Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy
Centofanti M; Oddone F; Chimenti S; Tanga L; Citarella L; Manni G
American Journal of Ophthalmology 2006; 142: 1059-1060
14732 Rescula as an alternative therapy for beta-blockers with long-term drift effect in glaucoma patients
Chen C-L; Tseng H-Y; Wu K-Y
The Kaohsiung Journal of Medical Sciences 2006; 22: 266-270
14719 Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma
Chen M-J; Cheng C-Y; Chen Y-C; Chou C-K; Hsu W-M
Journal of Ocular Pharmacology and Therapeutics 2006; 22: 188-193
14950 Adjunctive glaucoma therapy use associated with travoprost, bimatoprost, and latanoprost
Covert D; Robin AL
Current Medical Research and Opinion 2006; 22: 971-976
14415 A 3-month clinical trial comparing the IOP-lowering efficacy of bimatoprost and latanoprost in patients with normal-tension glaucoma
Dirks MS; Noecker RJ; Earl M; Roh S; Silverstein SM; Williams RD
Advances in Therapy 2006; 23: 385-394
15168 Clinical course of bimatoprost-induced periocular skin changes in Caucasians
Doshi M; Edward DP; Osmanovic S
Ophthalmology 2006; 113: 1961-1967
14548 Ocular hypotensive efficacy and safety of brinzolamide ophthalmic suspension 1% added to travoprost ophthalmic solution 0.004% therapy in patients with open-angle glaucoma or ocular hypertension
Franks W
Current Medical Research and Opinion 2006; 22: 1643-1649
14547 Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%
Garcia Feijoo J; Martinez De La Casa JM; Castillo A; Mendez C; Fernandez Vidal A; Garcia Sanchez J
Current Medical Research and Opinion 2006; 22: 1689-1697
15136 Short-term effects of latanoprost on anterior chamber depth in patients with glaucoma or ocular hypertension
Gutierrez-Ortiz C; Teus MA; Bolivar G
Investigative Ophthalmology and Visual Science 2006; 47: 4856-4859
14565 Travoprost/timolol
Hoy SM; Keam SJ; Keating GM
Drugs and Aging 2006; 23: 587-597
15267 Effects of latanoprost on rodent intraocular pressure
Husain S; Whitlock NA; Rice DS; Crosson CE
Experimental Eye Research 2006; 83: 1453-1458
15018 Adverse reaction after use of latanoprost in Japanese glaucoma patients
Inoue K; Wakakura M; Inoue J; Matsuo H; Hara T; Tomita G
Nippon Ganka Gakkai Zasshi 2006; 110: 581-587
15304 Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials
Li N; Chen XM; Zhou Y; Wei ML; Yao X
Clinical and Experimental Ophthalmology 2006; 34: 755-764
15314 Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase
Nakanishi Y; Nakamura M; Mukuno H; Kanamori A; Seigel GM; Negi A
Experimental Eye Research 2006; 83: 1108-1117
14901 Combined therapy in glaucoma treatment: travoprost 0.004% and brinzolamid
Popovic Suic S; Vukojevic N; Cerovski B; Jukic T
Acta Medica Croatica 2006; 60: 101-103
14490 The Slovak study of the travoprost treatment efficacy
Potocky M
Česka a Slovenska Oftalmologie 2006; 62: 263-269
14545 Comparison of the efficacy and safety of travoprost with a fixed-combination of dorzolamide and timolol in patients with open-angle glaucoma or ocular hypertension
Suzuki Jr ER; Franklin LM; Basilio Da Silva LJ; Figueiredo CRL; Netto JA; Batista WD
Current Medical Research and Opinion 2006; 22: 1799-1805
14436 A comparison of latanoprost monotherapy with a combination therapy of timolol/dorzolamide in patients with primary open-angle glaucoma
Caca I; Simsek H; Unlu K; Ari S; Keklikci U
Annals of ophthalmology (Skokie, Ill.) 2006; 38: 111-115
15176 Effect of latanoprost on the diurnal variations in the intraocular and ocular perfusion pressure in normal tension glaucoma
Ishibashi S; Hirose N; Tawara A; Kubota T
Journal of Glaucoma 2006; 15: 354-357

Issue 8-4

Change Issue


advertisement

WGA Rescources